Mohamed Wa’el Ahmed Hashad Purchases 10,638 Shares of Longeveron Inc. (NASDAQ:LGVN) Stock

Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa’el Ahmed Hashad acquired 10,638 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was bought at an average cost of $2.35 per share, with a total value of $24,999.30. Following the completion of the acquisition, the chief executive officer now directly owns 19,616 shares in the company, valued at $46,097.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Longeveron Stock Performance

LGVN opened at $1.69 on Friday. The firm has a market cap of $4.25 million, a P/E ratio of -0.17 and a beta of 0.21. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.50 and a current ratio of 1.50. Longeveron Inc. has a 52-week low of $1.62 and a 52-week high of $44.00. The business’s fifty day moving average is $4.32 and its 200-day moving average is $12.35.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.40). Longeveron had a negative net margin of 3,020.17% and a negative return on equity of 209.14%. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.21 million. Sell-side analysts expect that Longeveron Inc. will post -8.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LGVN. Citadel Advisors LLC bought a new stake in shares of Longeveron during the 4th quarter valued at approximately $44,000. Northern Trust Corp bought a new stake in Longeveron during the 2nd quarter worth $63,000. State Street Corp acquired a new position in Longeveron in the 2nd quarter worth about $88,000. Geode Capital Management LLC boosted its stake in shares of Longeveron by 78.6% during the second quarter. Geode Capital Management LLC now owns 66,392 shares of the company’s stock valued at $224,000 after purchasing an additional 29,212 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of Longeveron during the second quarter worth about $254,000. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.